Evidence map›Paper›PMID 41624976›Full record

ArticleJournal of hand surgery global online2026

Treatment of Dupuytren Contracture Recurrence After Surgery With Collagenase Clostridium Histolyticum: A Retrospective Multicenter Series.

Clayton A Peimer, Marie A Badalamente, Philip Blazar, Keith A Denkler, William Dzwierzynski, Mark Elzik, F Thomas D Kaplan, Jason A Nydick, Gary M Pess, James Verheyden and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hand surgery global online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Clayton A PeimerDepartment of Orthopedic Surgery, Warren Alpert Medical School, Brown University, Providence, RI.
Marie A BadalamenteDepartment of Orthopedics, Stony Brook University Medical Center, Stony Brook, NY.
Philip BlazarDepartment of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA.
Keith A DenklerDivision of Plastic and Reconstructive Surgery, University of California San Francisco, San Francisco, CA.
William DzwierzynskiDepartment of Plastic Surgery, Medical College of Wisconsin, Milwaukee, WI.
Mark ElzikSouth Orange County Orthopedics, Inc., Mission Viejo, CA.
F Thomas D KaplanIndiana Hand to Shoulder Center, Indianapolis, IN.
Jason A NydickFlorida Orthopedic Institute, Tampa, FL.
Gary M PessCentral Jersey Hand Surgery, Eatontown, NJ.
James VerheydenThe Center, Bend, OR.
Mark A VitaleONS Foundation for Clinical Research and Education, Greenwich, CT.
Jeffrey AndrewsEndo USA, Inc., A Keenova Therapeutics Company, Malvern, PA.
Qinfang XiangEndo USA, Inc., A Keenova Therapeutics Company, Malvern, PA.
David HurleyEndo USA, Inc., A Keenova Therapeutics Company, Malvern, PA.
Lawrence C HurstDepartment of Orthopedics, Stony Brook University Medical Center, Stony Brook, NY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Dupuytren contracture (DC) is a fibroproliferative disorder characterized by collagen deposition in the palmar fascia. Treatment options include collagenase clostridium histolyticum (CCH) injection and surgery; however, DC frequently recurs after primary therapy. We hypothesized that CCH treatment could be effective and well tolerated for the treatment of contracture recurrence for patients unwilling to undergo reoperation or at high risk for complications. Methods: This Phase 4, multicenter, noninterventional, retrospective study analyzed medical records from 10 clinical centers in the US. Patients were treated with CCH for DC recurrence ≥6 months after previously successful surgical correction performed between January 1, 2010, and August 15, 2020. Primary end points were the measured joint contracture change from baseline, at first and last clinical evaluation within 12 months of CCH treatment of metacarpophalangeal (MP) and proximal interphalangeal (PIP) joint contractures. Secondary end points were "clinical success" (percentage of joints with reduction in contracture to 0° to 5°) and adverse events. Results: Of 113 patients screened, 101 were analyzed (mean age, 64.1 years; 75% men). Median time to DC recurrence was 36.0 months. A total of 144 treated joints were analyzed (MP, Conclusions: This retrospective analysis indicates that CCH treatment is an effective and well tolerated nonsurgical option for recurrent postsurgical contracture, with results comparable to patients without prior surgery. Type of study/level of evidence: Therapeutic III.

Indexed as

Collagenase clostridium histolyticumDupuytren contractureMedical recordsRecurrenceRetrospective studies

Identifiers

PMID41624976
PMCPMC12859253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.